Canagliflozin shown to reduce CV, myocardial infarction and stroke

Canagliflozin shown to reduce CV, myocardial infarction and stroke
Credit: Shutterstock.com/ iko

Results from the CANVAS Programme showed Janssen-Cilag International’s Invokana significantly reduced the combined risk of cardiovascular death (CV), myocardial infarction and stroke.

The results also showed Invokana (canagliflozin) treatment was associated with a reduced risk of hospitalisation for heart failure and demonstrated potential renal protective effects.

The data from the integrated analysis of the CANVAS and CANVAS-R trials were published in the New England Journal of Medicine, and presented in a special symposium at the American Diabetes Association 77th Scientific Sessions.

Canagliflozin was studied in one of the largest completed CV outcomes programme of any sodium glucose cotransporter-2 (SGLT2) inhibitor.

The CANVAS Programme is the first to assess the long-term efficacy and safety of canagliflozin in more than 10,000 patients with T2DM, who had either a prior history of CV disease, or at least two CV risk factors.

The International Diabetes Federation estimates that, in 2015, over 59 million people were living with diabetes in Europe. If left uncontrolled, T2DM can lead to serious long-term microvascular and macrovascular complications.

Canagliflozin achieved a 14% reduction in the risk of the composite primary endpoint of CV death, nonfatal MI, or nonfatal stroke, and demonstrated an improved cardiovascular safety profile compared to placebo and superiority compared to placebo.

Each component evenly contributed to this risk reduction, including nonfatal MI by 15%, CV death by 13%, and nonfatal stroke by 10%. These outcomes were broadly consistent across various patient subgroups, and across the individual components of the primary endpoint.

“Patients with diabetes are two to four times more likely to suffer from associated comorbidities such as heart failure and kidney disease, and the CANVAS results demonstrate the potential of canagliflozin in reducing the risk for such conditions in high-risk type 2 diabetes patients,” said David Matthews, CANVAS Steering Committee co-chair, and Professor of Diabetic Medicine and Honorary Consultant Physician, University of Oxford.

He added: “These data are promising as they suggest canagliflozin may offer potential benefits for patients with type 2 diabetes, who are also facing complications from, or are at risk for, hospitalization for heart failure or kidney disease.”